Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Delcath Systems ( (DCTH) ) is now available.
On August 12, 2025, Delcath Systems, Inc. amended and restated its Bylaws to clarify procedural requirements for stockholder nominations and proposals, update officer election provisions, and describe indemnification rights. These changes aim to modernize and streamline the company’s governance framework, potentially impacting its operational efficiency and stakeholder engagement.
The most recent analyst rating on (DCTH) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Delcath Systems stock, see the DCTH Stock Forecast page.
Spark’s Take on DCTH Stock
According to Spark, TipRanks’ AI Analyst, DCTH is a Neutral.
Delcath Systems’ strong financial performance and positive earnings call are significant strengths. However, high valuation concerns and the lack of technical analysis data weigh down the overall score. Corporate events provide additional support, but historical financial volatility and valuation concerns remain key risks.
To see Spark’s full report on DCTH stock, click here.
More about Delcath Systems
Delcath Systems, Inc. operates in the medical technology industry, focusing on the development and commercialization of therapies for the treatment of primary and metastatic liver cancers.
Average Trading Volume: 773,743
Technical Sentiment Signal: Sell
Current Market Cap: $366.3M
See more insights into DCTH stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money